GLIGCA-FLIBGA REPORT AT THE DEPARTMENT OF CARDIOLOGY – CHỢ RẪY HOSPITAL

On December 18, 2025, Medbolide Pharmaceutical JSC attended the weekly scientific and technical seminar of the Department of Neurology at Chợ Rẫy Hospital. The seminar was attended by experts, doctors, and nurses from the Department of Neurology and was chaired by Deputy Head of Department and Specialist II Dr. Lê Nguyễn Nhựt Tín.

At the event, a representative from Medbolide gave a presentation on GLIGCA 25 (Milnacipran 25 mg)—a pain relief solution for the treatment of chronic pain and fibromyalgia syndrome (FM). GLIGCA 25, containing the active ingredient Milnacipran 25 mg, has been proven to be safe and effective in the treatment of chronic pain and fibromyalgia syndrome. In particular, Milnacipran does not cause cognitive impairment, does not lead to weight gain, causes few sleep disturbances, improves sexual function, and is well tolerated. This makes it easier for patients to adhere to treatment, thereby improving treatment outcomes.

In addition, the product overview of FLIBGA (Meclizine)—an effective solution for the treatment of acute and severe vestibular disorders—highlights the product’s key features: Equivalent efficacy to Diazepam; Active ingredient approved by the FDA since 1957; First-line treatment for severe vestibular disorders; Reduces dizziness and nausea within the first 7 days of the vestibular disorder.

The presentation drew the attention and praise of the doctors.

At the conclusion of the event, the company expressed its gratitude and looked forward to continuing to partner with the hospital in providing effective solutions to improve the quality of patient care. Medbolide Pharmaceutical JSC is proud to be a trusted partner of Cho Ray Hospital in supplying high-quality, effective medical products that contribute to the health and well-being of the community.